On May 4, 2021, HDT Bio announced that its development partner in India, Gennova Biopharmaceuticals, had begun dosing the first volunteers in a Phase I/II COVID-19 vaccine trial. HDT Bioﾒs innovative vaccine uses a proprietary Lipid InOrganic Nanoparticle (LION) formulation to deliver immune-stimulating RNA fragments to targeted cells.